Detail akcie Jupiter Neuroscn Rg online

Business Summary: Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Jupiter Neurosciences Inc revenues was not reported. Net loss increased from $912K to $6.1M. Higher net loss reflects General and administrative Balancing increase from $1.3M to $4M (expense), Research and development increase from $292K to $2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.03 to -$0.18.